NCT05942066 Feasibility Study Aiming at Pre-Analytical Standardization of Whole Blood Processing for Liquid Biopsy Applications
| NCT ID | NCT05942066 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tethis S.p.A. |
| Condition | Healthy Participants |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-10-09 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-10-09 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this feasibility study is to evaluate a new sample preparator called See.d. After blood processing the instrument will produce a set of slides and a tube of plasma. These outputs could be used in further analysis in liquid biopsy applications.
Eligibility Criteria
Inclusion Criteria: * Participants are willing and able to give and sign a written informed consent * Aged 18 or above Exclusion Criteria: * Ongoing infections requiring antibiotic or antiviral treatment * Known hemostasis/coagulation disorder * Known Pregnancy
Contact & Investigator
Luca Santoleri, MD
PRINCIPAL INVESTIGATOR
Ospedale San Raffaele
Frequently Asked Questions
Who can join the NCT05942066 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05942066 currently recruiting?
Yes, NCT05942066 is actively recruiting participants. Contact the research team at MEDICI.CDS@HSR.IT for enrollment information.
Where is the NCT05942066 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT05942066 clinical trial?
NCT05942066 is sponsored by Tethis S.p.A.. The principal investigator is Luca Santoleri, MD at Ospedale San Raffaele. The trial plans to enroll 200 participants.